Screener
Halozyme Therapeutics HALO Gross Carrying Amount
Gross Carrying Amount at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Weighted Average Useful Life (in years) | Gross Carrying Value | Accumulated Amortization | Net Carrying Value |
|---|---|---|---|---|
| Auto-injector technology platform | 7 | $402,000 | $235,735 | $166,265 |
| XYOSTED proprietary product | 10 | 136,200 | 55,908 | 80,292 |
| Hypercon developed technology platform | 15 | 230,000 | 9,498 | 220,502 |
| Customer relationships (1) | 15 | 470,000 | 19,410 | 450,590 |
| Trade name | 15 | 5,000 | 206 | 4,794 |
| Total intangible assets, net | $1,243,200 | $320,757 | $922,443 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's gross carrying amount?
- Halozyme Therapeutics (HALO) reported gross carrying amount of $1.24B in Q2 2026.
- How has Halozyme Therapeutics's gross carrying amount changed year-over-year?
- Halozyme Therapeutics's gross carrying amount increased by 131.0% year-over-year, from $538.2M to $1.24B.
- What does gross carrying amount mean?
- Gross Carrying Amount
Ask your AI about Halozyme Therapeutics's gross carrying amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude